Eloralintide
Eloralintide is a peptide, indexed here under Amylin and amylin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Amylin and amylin receptor agonists |
| CAS registry number | 2883634-40-8[1] |
| PubChem CID | 175663130[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C201H319N49O65S2[1] |
| Molecular weight | 4526 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Eloralintide, development code LY3841136, is described in a 2025 Molecular Metabolism paper as a novel amylin receptor agonist, covering discovery to clinical proof of concept. Its retrieved literature is small and recent.
A 2026 Diabetes, Obesity and Metabolism paper reports a phase 1 proof of concept study, a 2025 Lancet paper reports a 48-week phase 2 multicentre double-blind trial in obesity describing it as a selective amylin receptor agonist, and a 2026 Cardiology in Review article discusses cardiometabolic implications of selective amylin receptor agonism.
[3, 4, 5, 6]Reported mechanism
A selective, long-acting amylin receptor agonist, per the retrieved records.
[5, 4]Stated in the titles of the cited 2025 Lancet and 2026 Diabetes, Obesity and Metabolism papers.
Targets named in the cited records: amylin receptors.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Eloralintide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- LY3841136
Where this page sits
Research records
Cited research records for Eloralintide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Petrelintide — Amylin and amylin receptor agonists
- Cagrilintide — Amylin and amylin receptor agonists
Class page: Amylin and amylin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Eloralintide?
Eloralintide, development code LY3841136, is described in a 2025 Molecular Metabolism paper as a novel amylin receptor agonist, covering discovery to clinical proof of concept. Its retrieved literature is small and recent.
Which class is Eloralintide indexed under?
Eloralintide is indexed under Amylin and amylin receptor agonists. This class groups the pancreatic hormone amylin, also called islet amyloid polypeptide, and the synthetic analogues modelled on it.
What does the FDA application register show for Eloralintide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 175663130, Eloralintide. PubChem, National Library of Medicine (2026). pubchem:175663130
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:eloralintide
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular metabolism (2025). pmid:41109426
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, obesity & metabolism (2026). pmid:41559929
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) (2025). pmid:41207310
- Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide. Cardiology in review (2026). pmid:42745233
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.